Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefoxitin
Drug ID BADD_D00393
Description Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.
Indications and Usage For the treatment of serious infections caused by susceptible strains microorganisms.
Marketing Status approved
ATC Code J01DC01
DrugBank ID DB01331
KEGG ID D02345
MeSH ID D002440
PubChem ID 441199
TTD Drug ID D02VFC
NDC Product Code 25021-111; 25021-110; 0143-9876; 44567-245; 66288-4100; 0143-9877; 44567-246; 44567-247; 0143-9878; 25021-109
UNII 6OEV9DX57Y
Synonyms Cefoxitin | MK-306 | MK 306 | MK306 | Cefoxitin Sodium | Sodium, Cefoxitin | Mefoxin | Méfoxin | Mefoxitin
Chemical Information
Molecular Formula C16H17N3O7S2
CAS Registry Number 35607-66-0
SMILES COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemolytic anaemia01.06.03.002--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Injection site reaction12.07.03.015; 08.02.03.014--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Local reaction08.01.03.012--Not Available
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.001--
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Neutropenia01.02.03.004--Not Available
Pain08.01.08.004--
Pancytopenia01.03.03.003--Not Available
Phlebitis24.12.03.004; 12.02.01.002--
Prothrombin level increased13.01.02.011--Not Available
Prothrombin time prolonged13.01.02.012--Not Available
Pruritus23.03.12.001--
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Seizure17.12.03.001--
Serum sickness12.02.08.004; 10.01.03.004--
Serum sickness-like reaction10.01.03.005; 08.01.03.003--Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Superinfection11.01.08.009--Not Available
Tachycardia02.03.02.007--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene